Headquartered in Lyon, France, Aurobac Therapeutics aims to develop a new precision medicine approach to antibiotic treatment, from diagnosis to cure. The joint-venture is majority-funded […]
The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out. […]
Over the years, the incidence and prevalence of chronic diseases, have increased significantly. Presently, the recommended treatment options for such clinical conditions are mostly biologics, […]
In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the […]
I previously covered research from Dickson and Kent (2021) that examined how the entry of generic drugs impacts the price Medicare pays. In that study, […]
Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients […]
By Christopher Weikart, Chief Scientist at SiO2 Materials Science Why is an incredibly innovative and forward-thinking industry like pharmaceuticals being held back by the products […]
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter into this market. […]
The FDA has approved the first biosimilar that references the blockbuster Roche drug Lucentis. The Biogen and Samsung BioLogics joint venture that developed the biologic […]
Like generic drugs for small molecules, biosimilars offer the hope for reducing drug prices after biologic therapies lose their patent protections. But how big an […]
SOMERSET, N.J. — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it […]
A paper from Nayak et al. (2021) in JAMA Internal Medicine describes how public-private partnerships have helped bring new biologic drugs to market. Using data […]
This panel highlights how different organizations in the biopharma supply chain are addressing the inherent challenges of producing and delivering cell and gene therapies and […]
Cell and gene therapy companies already faced challenges in finding efficient ways to manufacture these new treatments. Then, the pandemic made these vulnerabilities even more […]
Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are […]
Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized […]
The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of […]
In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: the permanent changes in […]
The recent years have portrayed the renaissance in the domain of microbial fermentation, as microbial biopharma industry has once again gained attention towards the production […]
The gradual shift of healthcare industry towards the development of biologics is a well-known fact. Owing to this shift, there are over 1,000 cell and […]
Copyright © 2024 | WordPress Theme by MH Themes
